Drug - IBRANCE™ (palbociclib capsules) [Pfizer]
Therapeutic area - Oncology
21 capsules every 28 days
IBRANCE is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
MHCP Provider Call Center 651-431-2700 or 800-366-5411